Abingdon Health Plc logo

Abingdon Health Plc(LSE) ABDX

Market Cap£41.33MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-91%
5 Year-84%
1 Year+36%
1 Month-23%
£0.09
-10.53%
-0.01Today
Abingdon Health Plc last closing stock price
MetricPriceDate
Last closeGBX 8.502026-10-14
Abingdon Health Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-20.93%GBX 10.752026-10-07
1 month-22.73%GBX 11.002026-09-14
3 month-12.82%GBX 9.752026-07-16
Year to date+32.81%GBX 6.402025-12-31
1 year+36%GBX 6.252025-10-14
3 year-26.09%GBX 11.502023-10-13
5 year-83.76%GBX 52.342021-10-15
Since inception-90.97%GBX 1.052020-12-15

Abingdon Health Plc Financials at a Glance

Market Cap

£41.33MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£16.39M

Net Income (TTM)

-£5.83M

EPS (TTM)

-£0.01

P/E Ratio

-17.59

Dividend

£0.00

Beta (Volatility)

-0.03 (Low)

Price

£0.09

Volume

161,580

Open

£0.09

Previous Close

£0.10

Daily Range

£0.09 - £0.10

52-Week Range

£0.06 - £0.13

Estimated Earnings Date

Nov 18, 2026

ABDX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Abingdon Health Plc

Abingdon Health Plc is a UK-based company specializing in the development and distribution of diagnostic instruments. Established in 2008, the company focuses on innovative solutions for rapid testing, particularly in the healthcare sector.

Products and Services
  • AbC-19 Rapid Test for COVID-19 IgG antibodies
  • Seralite for measuring immunoglobulin free light chains in blood serum
  • AppDx technology for smartphone-based lateral flow reading
Growth Outlook
  • Recent revenue of £4.24 million indicates a recovery trend
  • Strong demand for rapid testing solutions supports future growth
  • Partnerships with health tech firms enhance market reach
Financial Highlights
  • Trailing twelve months revenue of £19.5 million shows potential
  • Current ratio of 1.91 suggests good short-term financial health
  • Net income loss of £2.35 million in the latest quarter reflects ongoing challenges
Abingdon Health Plc operates in the medical diagnostics and research industry, providing essential products that cater to the growing demand for rapid testing solutions. The company has made significant strides in developing innovative diagnostic tools, particularly in response to the COVID-19 pandemic. The AbC-19 Rapid Test and Seralite are key products that highlight the company's commitment to addressing urgent healthcare needs. The growth outlook for Abingdon Health is promising, with recent revenue figures indicating a recovery and strong demand for its products. The company's partnerships within the health tech sector further enhance its market presence and potential for expansion. Financially, while the company reported a net income loss in the latest quarter, the current ratio suggests a solid position to meet short-term obligations. The trailing twelve months revenue indicates a substantial market opportunity, positioning Abingdon Health as a noteworthy player in the diagnostics field. Overall, Abingdon Health Plc presents an intriguing opportunity for investors interested in the healthcare sector, particularly in the rapidly evolving diagnostics market.
AI Generated • Sep 25, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

CEO

Chris Henry Francis Yates

Website

www.abingdonhealth.com

Headquarters

York, YK YO41 1LZ, GB

ABDX Financials

Key Financial Metrics (TTM)

Gross Margin

34.11%

Operating Margin

-45.70%

Net Income Margin

-33.88%

Return on Equity

-55.91%

Return on Capital

-63.61%

Return on Assets

-30.73%

Earnings Yield

-5.69%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£41.33MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

435.07M

Volume

161.58K

Avg. Volume

117.02K

Financials (TTM)

Gross Profit

£6.44M

Operating Income

-£6.85M

EBITDA

-£5.04M

Operating Cash Flow

-£4.85M

Capital Expenditure

-£369.00K

Free Cash Flow

-£5.22M

Cash & ST Invst.

£3.71M

Total Debt

£948.00K

Abingdon Health Plc Performance Analysis

Abingdon Health Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30GBP 4,045,00042.7%
20242024-06-30GBP 6,135,00051.7%
20252025-06-30GBP 8,429,00037.4%
20262026-06-30GBP 10,993,00030.4%
Abingdon Health Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3054.6%
Q22024-12-31-16.9%
Q42025-06-3072.4%
Q22025-12-31-20.6%
Abingdon Health Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30GBP -0.01-84.4%
20242024-06-30GBP -0.00-63.2%
20252025-06-30GBP -0.01121.4%
20262026-06-30GBP -0.01-45.2%
Abingdon Health Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3094.9%
Q22024-12-31-3450.0%
Q42025-06-3066.2%
Q22025-12-31-150.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

£4.24M

+75.8%

Gross Profit

£1.05M

-17.5%

Gross Margin

24.88%

N/A

Market Cap

£41.33MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£365.77K

N/A

Employees

113

N/A

Net Income

-£2.35M

-94.9%

EBITDA

-£2.50M

-177.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

£3.71M

+85.5%

Total Debt

£948.00K

-6.0%

Accounts Receivable

£2.35M

+135.5%

Inventory

£638.00K

+55.2%

Long Term Debt

£658.00K

-27.8%

Short Term Debt

£290.00K

+199.0%

Return on Assets

-30.73%

N/A

Return on Invested Capital

-62.02%

N/A

Free Cash Flow

-£1.31M

-7.5%

Operating Cash Flow

-£1.28M

-7.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PXS.LProvexis plc
£0.01+0.00%
IXI.LIXICO plc
£0.08+0.00%
GDR.LGenedrive Plc
£0.01-2.78%
COG.LCambridge Cognition Holdings Plc
£0.29+3.57%

Trending Stocks

Symbol / CompanyPricePrice Chg
CRWVCoreWeave
$67.02-13.87%
BACBank of America
$49.74-7.83%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$40.19+7.41%
CIFRCipher Digital
$10.54-7.08%

Questions About ABDX

What is the current price of Abingdon Health Plc?

Abingdon Health Plc is trading at £0.09 per share.

What is the 52-week range for Abingdon Health Plc?

Over the past 52 weeks, Abingdon Health Plc has traded between £0.06 and £0.13.

How much debt does Abingdon Health Plc have?

As of the most recent reporting period, Abingdon Health Plc reported total debt of £1.34M.

How much cash does Abingdon Health Plc have on hand?

Abingdon Health Plc reported £2.87M in cash and cash equivalents in its most recent financial results.

What is Abingdon Health Plc’s dividend yield?

Abingdon Health Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services